RxDoctor Payments Data

Julie Ainsworth, NP

Nurse Practitioner · Gulfport, MSNPI 1134717622

Payments from drug & device makers

$2,102in general payments, 2019–2025

Across 113 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$380
  • Johnson & Johnson$232
  • Merck$216
  • E.r. Squibb & Sons, L.L.C.$179
  • Pfizer$150
  • Boehringer Ingelheim$138
  • plus $808 from 15 others
$1,756in research payments, 2019–2025

Across 13 payments — averaging $135.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$2K

What the payments were for

  • Food & beverage$2,02796%
  • Gifts$754%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,102 in reported general payments places this provider in the 85th percentile of 1,090 nurse practitioner providers in Mississippi.

See all nurse practitioner providers in Mississippi

Medicare billing

Part B allowed, 2024
$9,545
Medicare patients
99
Services billed
132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban31$36,762
XareltoRivaroxaban15$14,737
Atorvastatin Calcium51$654
Amiodarone Hcl11$482
Metoprolol Succinate26$265
ClopidogrelClopidogrel Bisulfate16$256
Metoprolol Tartrate26$243
Ezetimibe17$234
Losartan Potassium17$157
Spironolactone20$122
Lisinopril22$113
Rosuvastatin Calcium16$87
Amlodipine Besylate36$83
Carvedilol14$55
Furosemide20$43

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$150$36,76231 claims
Johnson & JohnsonXarelto$232$14,73715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,090 nurse practitioner providers in Mississippi.

Other nurse practitioner in Gulfport

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →